Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMGLNASDAQ:BRTXNASDAQ:OPGNNASDAQ:PIII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMGLBasel Medical Group$2.43-9.0%$3.54$0.91▼$9.40$49.28MN/A14.69 million shs371,173 shsBRTXBiorestorative Therapies$1.58-7.1%$1.74$1.21▼$2.55$12.76M76.75147,990 shs96,772 shsOPGNOpGen$4.88$4.75$0.53▼$5.25$49.13M-1.689,599 shs11,801 shsPIIIP3 Health Partners$6.33+2.0%$7.85$6.20▼$32.54$44.57M0.8420,192 shs1,466 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMGLBasel Medical Group-8.99%-29.77%+29.95%+242,999,900.00%+242,999,900.00%BRTXBiorestorative Therapies-7.06%-5.95%+1.94%-10.23%-22.17%OPGNOpGen0.00%-1.21%0.00%+82.77%+92.89%PIIIP3 Health Partners+2.02%-1.77%-19.01%-26.45%-79.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ABRTXBiorestorative Therapies3.7254 of 5 stars3.55.00.00.03.13.30.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.5102 of 5 stars3.34.00.00.01.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMGLBasel Medical Group 0.00N/AN/AN/ABRTXBiorestorative Therapies 3.00Buy$18.001,039.24% UpsideOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25156.92% UpsideCurrent Analyst Ratings BreakdownLatest BRTX, OPGN, BMGL, and PIII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/ABRTXBiorestorative Therapies$400K29.63N/AN/A$1.23 per share1.28OPGNOpGen$2.67M18.38N/AN/A($11.55) per share-0.42PIIIP3 Health Partners$1.50B0.03N/AN/A$10.58 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMGLBasel Medical GroupN/AN/A0.00∞N/AN/AN/AN/AN/ABRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PIIIP3 Health Partners-$135.85M-$47.28N/AN/AN/A-9.27%-123.10%-15.94%8/6/2025 (Estimated)Latest BRTX, OPGN, BMGL, and PIII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million3/27/2025Q4 2024BRTXBiorestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMGLBasel Medical GroupN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMGLBasel Medical GroupN/AN/AN/ABRTXBiorestorative TherapiesN/A2.242.24OPGNOpGenN/A5.455.45PIIIP3 Health Partners1.680.380.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMGLBasel Medical GroupN/ABRTXBiorestorative Therapies69.38%OPGNOpGen2.68%PIIIP3 Health Partners7.75%Insider OwnershipCompanyInsider OwnershipBMGLBasel Medical GroupN/ABRTXBiorestorative Therapies25.50%OPGNOpGen43.80%PIIIP3 Health Partners17.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMGLBasel Medical Group3618.45 millionN/AN/ABRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.19 million5.91 millionNot OptionableBRTX, OPGN, BMGL, and PIII HeadlinesRecent News About These CompaniesWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 16, 2025 | globenewswire.comBears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' NowJune 12, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 6, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 3, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 27, 2025 | globenewswire.comDown 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)May 26, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 23, 2025 | globenewswire.comP3 Health Partners Inc. (NASDAQ:PIII) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Report Preview: What To Look ForMay 16, 2025 | finance.yahoo.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Call Highlights: Strategic Adjustments and ...May 16, 2025 | finance.yahoo.comP3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025May 16, 2025 | msn.comP3 Health Partners Inc. (PIII) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comP3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comP3 Health Partners Announces First Quarter 2025 ResultsMay 15, 2025 | businesswire.comP3 Health Partners price target lowered to $20 from $50 at Lake StreetApril 21, 2025 | markets.businessinsider.comP3 Health Partners (PIII) Stock Jumps 8.9%: Will It Continue to Soar?April 16, 2025 | zacks.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Inc trading halted, news pendingApril 12, 2025 | markets.businessinsider.comP3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRTX, OPGN, BMGL, and PIII Company DescriptionsBasel Medical Group NASDAQ:BMGL$2.43 -0.24 (-8.99%) As of 06/20/2025 04:00 PM EasternBasel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.Biorestorative Therapies NASDAQ:BRTX$1.58 -0.12 (-7.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.61 +0.03 (+1.90%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.OpGen NASDAQ:OPGN$4.88 0.00 (0.00%) As of 06/20/2025 03:51 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$6.32 +0.13 (+2.02%) Closing price 06/20/2025 03:58 PM EasternExtended Trading$6.54 +0.21 (+3.38%) As of 06/20/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
